This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or a history of malignancy). (Cibinqo Summary of Product Characteristics)
JADE DARE is the first head-to-head clinical trial designed to assess the efficacy and safety of abrocitinib 200mg per day versus dupilumab 300 mg every two weeks in adults with moderate-to-severe-atopic dermatitis. It is also the first comparative trial of a JAK inhibitor versus dupilumab for moderate to severe atopic dermatitis in patients receiving background topical therapy, which reflects real world practice.1
Study design1
Randomised, double-blind, double-dummy, active-controlled, head-to-head phase III trial that compared the efficacy and safety of Cibinqo 200 mg + TCS vs dupilumab TCS in 727 adult patient with moderate-to-severe AD.
*TCS includes low - to medium-potency topical corticosteriods and other medicated topicals, which were required per study protocol. Non-medicated topicals were also required. Participants with intolerable AD symptoms were eligible to receive rescue therapy after Week 4, which indcluded high-potency TCS for up to 2 weeks, systemic corticosteriods for up to 10 days, or other systemic therapy. 1
†Patients randomised to dupilumab received a loading dose of 600mg. 1
PP-NRS4 response defined as ≥4- point improvement from Baseline;EASI-90 response defined as ≥90% improvement from baseline.
†TCS: includes low - to medium-potency topical corticosteriods and other medicated topicals, which were required per study protocol.1
BSA=body surface area. DLQI=Dermatology Life Quality Index. EASI=Eczema Area and Severity Index. IGA=Investigator’s Global Assessment.
PP-NRS=Peak Pruritus Numerical Rating Scale. SD=standard deviation.
Cibinqo demonstrated superior itch relief compared to dupilumab1
In a randomised, double-blind, head-to-head, comparative (Cibinqo 200 mg once-daily + TCS vs dupilumab 300 mg Q2W + TCS), Phase III trial of 727 adult patients with moderate to severe AD, at Week 2 a significantly greater proportion of patients treated with Cibinqo 200 mg once-daily + TCS achieved PP-NRS4 compared to dupilumab 300 mg Q2W + TCS (48% (n=172/357) vs 26% (n=93/364); P<0.0001).1
PP-NRS4 response at week 2 vs dupilumab (primary endpoint):
Adapted from Reich K, et al. Lancet 2022;400:273-282
Patient who withdrew from the study or used rescure therapy were considered as non-responders after that point. Intermittent imssing values were not imputed. Error bars represent 95% CIs.1
†TCS: Includes low - to medium-potency topical corticosteriods and other medicated topicals, which were required per study protocol.1
One day after the first dose, significantly more patients achieved itch relief with Cibinqo than with dupilumab1
In an additional multiplicity-controlled analysis, one day after the first dose the proportion of patients who reached PP-NRS4 was significantly higher in the Cibinqo 200 mg once-daily + TCS group than
in the dupilumab 300 mg Q2W + TCS group (11% (n=35/319) vs 4% (n=12/317); P=0.0006).1
The figure below depicts the percentage of patients who achieved an EASI-90 response, defined as ≥90% improvement in EASI scores from baselines through week 26 for each of the treatment groups.1
Figure 1 - Proportion of patient achieving EASI 90 from baseline
Example
Adapted from Reich K, et al. Lancet 2022;400:273-282
†TCS: includes low - to medium-potency topical corticosteriods and other medicated topicals, which were required per study protocol. Non-medicated topicals were also required.1
At week 4 (primary endpoint):
JADE DARE Safety and Tolerability
a.Includes events that lead to death or serious deterioration in the participant's health, or to distress or death of a foetus or a congenital abnormality or birth defect.
b.Includes events that prevent normal everyday activites.
c.Includes events classified as acne pustular, folliculitis, acne, and dermatitis acneiform.
d.Includes events classified as allergic keratitis, conjunctival haemorrhage, conjunctivitis allergic, keratisis, noninfective conjunctivitis, ocular hyperaemia, conjunctivities, conjunctivities bacterial and conjunctivties viral.
Access safety information on abrocitinib.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.
Learn more about flexible dosing in patients on Cibinqo.
AD=atopic dermatitis; EASI=Eczema Area and Severity Index; TCS=Topical corticosteriod; PP-NRS=Peak Pruritus Numerical Rating Scale.
References:
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.